Key result
Three-component fixed-dose antihypertensive and lipid-lowering therapy improves compliance in high CV risk patients.
Why the study?
Many patients with arterial hypertension and hyperlipidemia lack adequate control of blood pressure and atherogenic lipoprotein fractions, prompting review of fixed combinations to optimize pharmacotherapy and compliance.
Does the use of fixed-dose combinations of antihypertensive and hypolipidemic drugs improve treatment compliance and risk factor control in patients with high cardiovascular risk?
Does the use of fixed-dose combinations of antihypertensive and hypolipidemic drugs improve treatment compliance and risk factor control in patients with high cardiovascular risk?
Fixed-dose combinations of antihypertensive and lipid-lowering therapies may improve treatment compliance and risk factor control in high-risk cardiovascular patients.
Answers are grounded in this paper and cite their sources.
Supports adherence with fixed-dose combinations in high-risk patients; leaves open need for outcome trials before practice change.
This review focuses on the role of arterial hypertension and hyperlipidemia as the most important risk factors of early disability and death. The facts are provided that many persons with those risk factors do not have the adequate control of blood pressure and atherogenic fractions of blood serum lipoproteins. The review addresses prospects for optimizing pharmacotherapy with fixed combinations of drugs for arterial hypertension and dyslipidemia. From the perspective of effective clinical guidelines and the available evidence base, the authors reviewed possibilities for improving the treatment compliance by using combinations of antihypertensive and hypolipidemic drugs in a single dosage form. Implementation of such complex, optimized treatment using a three-component fixed-dose combination is considered.
No takes yet. Share an insight, caveat, or question.
Поветкин et al. (2022) conducted a review in Arterial hypertension and hyperlipidemia. Three-component fixed-dose combination of antihypertensive and hypolipidemic drugs was evaluated. Optimizing pharmacotherapy with a three-component fixed-dose combination of antihypertensive and hypolipidemic drugs improves treatment compliance in patients with high cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: